Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brümmendorf, Tim H., Gambacorti-Passerini, Carlo, Bushmakin, Andrew G., Cappelleri, Joseph C., Viqueira, Andrea, Reisman, Arlene, Isfort, Susanne, Mamolo, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237399/
https://www.ncbi.nlm.nih.gov/pubmed/32307568
http://dx.doi.org/10.1007/s00277-020-04018-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237399/
https://www.ncbi.nlm.nih.gov/pubmed/32307568
http://dx.doi.org/10.1007/s00277-020-04018-1

Ejemplares similares